GSK’s Arexvy is a fRespiratory syncytial virus vaccine, adjuvanted, contains a recombinant subunit prefusion RSV F glycoprotein antigen (RSVPreF3) combined with GSK’s proprietary AS01E adjuvant.
trials continue to evaluate an annual revaccination schedule and protection/immunogenicity over multiple seasons following one dose of the RSV vaccine.
yet, another damn annual vaccine with a secret-sauce adjuvant, which is a chemical designed to hyperstimulate the immune system because the basic vaccine is too weak to work without it ...
and of course, the super efficacy claimed in the trials will likely drop to a fraction of those claims in real life, if this vaccine follows the pattern of influenza and covid vaccines ...
worse, though, both pfizer and moderna have mRNA RSV vaccines they’re trying to get accelerated approval for ...
all of this for an illness that knocks off 6,000-14,000 old folks each year like me who have a shitpile of comorbidities ...
we had RSV blow through my area a few months ago and awhole bunch of gave it to each other (it’s highly communicable), and it did in fact go down into our lungs and we were very ill, but no one that i know died from it ... unfortunately, immunity from subsequent infection only lasts a year or so like influenza ... though i don’t know if the immunity wanes or the virus mutates ...
Probably both...................